Alendronate Sodium Tablet
Product Images NDC 70518-1192

9 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 70518-1192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Structure)

1 (Structure)
Chemical structure of Alendronate sodium, showing its molecular arrangement including amino, phosphate groups, and sodium hydrate components.*
FDA Label Image

Fracture (Fig1 1)

Fracture (Fig1 1)
A line chart showing the cumulative incidence of hip fractures over a 36-month period in patients with baseline radiographic vertebral fractures. The chart compares two groups: Placebo (dashed line) and Alendronate Sodium (solid line), with cumulative incidence (%) on the vertical axis and time in months on the horizontal axis. The Placebo group shows a higher cumulative incidence than the Alendronate Sodium group over time.*
FDA Label Image

Treatment (Figure1 2)

Treatment (Figure1 2)
A bar chart comparing mean percent increase in Bone Mineral Density (BMD) relative to placebo between U.S. and multinational groups at three bone sites: Lumbar Spine, Femoral Neck, and Trochanter. The chart includes error bars representing standard error (SE) for each measurement.*
FDA Label Image

Postmenopausal (Figure1 3)

Postmenopausal (Figure1 3)
Two line graphs titled 'US Study' and 'Multinational Study' showing mean percentage change in bone mineral density (BMD) from baseline over 36 months. Both graphs compare Alendronate Sodium 10 mg versus placebo, with Alendronate Sodium showing an increasing BMD trend, while placebo remains near baseline.*
FDA Label Image

5 (Fig 1 4)

5 (Fig 1 4)
Two bar charts comparing the change in bone mineral density (BMD) from baseline in postmenopausal women treated with Alendronate Sodium 5 mg/day versus placebo. The left chart shows results from a 2-year study, and the right chart from a 3-year study, across lumbar spine, femoral neck, trochanter, and total body sites, with mean percentage change and standard error displayed.*
FDA Label Image

6 (Fig1 5)

6 (Fig1 5)
A bar chart titled 'Studies in Glucocorticoid-Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year' comparing mean percentage increase in bone mineral density (BMD) relative to placebo across three sites: Lumbar Spine, Femoral Neck, and Trochanter. The chart shows data for U.S. and Multinational groups, with Multinational having higher BMD increases in all three regions.*
FDA Label Image

7 (Fig 1 6)

7 (Fig 1 6)
A line graph showing the effect of Alendronate Sodium 40 mg/day versus placebo and Etidronate 400 mg/day on serum alkaline phosphatase levels over a 6-month period in studies of Paget's Disease of Bone. The y-axis indicates mean percent change from baseline in serum alkaline phosphatase, and the x-axis represents time in months. Multiple study groups, including placebo, Etidronate 400 mg/day, and two Alendronate Sodium 40 mg/day studies (multinational and U.S.), are plotted with different trends.*
FDA Label Image

Mm1 (Alendronate Sodium 35mg 70518 1192 00)

Mm1 (Alendronate Sodium 35mg 70518 1192 00)
Packaging label for Alendronate Sodium 35 mg tablets, containing 4 tablets. The label shows the generic name, strength, and quantity. It includes manufacturer information (Cipla USA, Inc.) and repackager details (RemedyRepack Inc., Indiana, PA). Storage instructions and a QR code are also visible.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Alendronate Sodium 35 mg oral tablets, showing a quantity of 12 tablets. The label includes manufacturer info (Cipla Ltd, Kurkumbh, India) and repackager details (RemedyRepack Inc., Indiana, PA). It features dosage form, strength, barcode, NDC number, warnings to keep out of children's reach, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.